Premium
Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
Author(s) -
Flaherty Keith T.
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24688
Subject(s) - sorafenib , medicine , renal cell carcinoma , interferon , oncology , value (mathematics) , randomized controlled trial , cancer research , immunology , hepatocellular carcinoma , machine learning , computer science
Sorafenib can be combined safely with interferon, but the results of a recent randomized, phase 2 trial cast doubt on the value of further evaluating this combination. The renal cell carcinoma field continues to wrestle with the value of combining “targeted” therapies with cytokines.